# Phase 2 kidney cancer trials recruiting: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 2 for kidney cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 kidney cancer trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/kidney-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 2, 2026 | NCT07909265 | Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909265) |
| October 13, 2026 | NCT07870746 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Not yet recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870746) |
| September 18, 2026 | NCT07828704 | Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA | Henry Ford Health System | Phase 2 | Recruiting | Kidney Cancers | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828704) |
| July 20, 2026 | NCT07715565 | Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell... | West China Hospital | Phase 2 | Not yet recruiting | Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715565) |
| June 29, 2026 | NCT07672860 | Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors | Jinling Hospital, China | Phase 2 | Recruiting | Kidney Cancer | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672860) |
| February 9, 2026 | NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397611) |
| November 5, 2025 | NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Breast Cancer, Kidney Neoplasms, Liver Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225114) |
| August 14, 2025 | NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123090) |
| July 22, 2025 | NCT07077083 | CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC | Massachusetts General Hospital | Phase 2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077083) |
| July 18, 2025 | NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | Psyence Australia Pty Ltd | Phase 2 | Recruiting | Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia, Cancer of Endometrium, Cancer of... | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072728) |
| July 3, 2025 | NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | The Methodist Hospital Research Institute | Phase 2 | Recruiting | Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07050771) |
| May 8, 2025 | NCT06962787 | A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Renal Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962787) |
| April 29, 2025 | NCT06948552 | Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA | Henry Ford Health System | Phase 2 | Recruiting | Upper Tract Urothelial Carcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948552) |
| February 28, 2025 | NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | RenJi Hospital | Phase 2 | Recruiting | Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06852638) |
| January 20, 2025 | NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | Recruiting | Metastatic Clear Cell Renal Cell Carcinoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06783348) |
| November 12, 2024 | NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | Fudan University | Phase 2 | Recruiting | Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06683846) |
| November 8, 2024 | NCT06680089 | CD70-targeted immunoPET Imaging of Kidney Cancer | RenJi Hospital | Phase 2 | Recruiting | Urologic Neoplasms, Urogenital Neoplasms, Kidney Neoplasms, Neoplasms | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680089) |
| November 1, 2024 | NCT06670300 | Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06670300) |
| August 30, 2024 | NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580002) |
| January 18, 2024 | NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | Fudan University | Phase 2 | Recruiting | Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06211790) |
| August 1, 2023 | NCT05969496 | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus | University of Colorado, Denver | Phase 2 | Recruiting | Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05969496) |
| February 15, 2022 | NCT05241561 | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients | Centre Hospitalier Universitaire de Besancon | Phase 2 | Not yet recruiting | Cancer of Kidney | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05241561) |
| December 26, 2018 | NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03786796) |
| June 5, 2017 | NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Apollomics Inc. | Phase 2 | Recruiting | Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung... | 497 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03175224) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Henry Ford Health System | 2 |
| Fudan University | 2 |
| RenJi Hospital | 2 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Massachusetts General Hospital | 1 |
| [Telix Pharmaceuticals (Innovations) Pty Limited](https://specstream.ai/data/clinical-trials/company/telix-pharmaceuticals-innovations-pty-limited) | 1 |
| Psyence Australia Pty Ltd | 1 |
| West China Hospital | 1 |
| University of Colorado, Denver | 1 |
| University of California, Irvine | 1 |
| Jinling Hospital, China | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| The Methodist Hospital Research Institute | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Dana-Farber Cancer Institute | 1 |
| Apollomics Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 9 |
| France | 3 |
| Australia | 2 |
| Canada | 1 |
| Hungary | 1 |
| Italy | 1 |
| Russia | 1 |
| Singapore | 1 |
| Spain | 1 |
| Taiwan | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B radio and television commercials companies in the United States](https://specstream.ai/data/businesses/b2b-radio-and-television-commercials-companies/united-states)
- [Vehicle shipping companies in the United States](https://specstream.ai/data/businesses/vehicle-shipping-companies/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
- [Inventory control companies in the United States](https://specstream.ai/data/businesses/inventory-control-companies/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
